Sponsor content
193 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RETEVMO selpercatinib 120 mg film-coated tablets blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL + 200 mg/2 mL solution for injection pre-filled syringe (composite pack) (citrate free formulation).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL solution for injection pre-filled syringe (citrate-free formulation).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL + 200 mg/2 mL solution for injection autoinjector (pre-filled pen) composite pack (citrate-free formulation).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL solution for injection autoinjector (pre-filled pen) (citrate-free formulation).
-
Prescription medicine registrationActive ingredients: selpercatinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial.
-
Sep-2025Prescription medicine evaluationActive ingredient: tirzepatide.
-
Prescription medicine registrationActive ingredients: mirikizumab.
-
Australian public assessment report (AusPar)Kisunla (donanemab) has been approved for the treatment of patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia (early symptomatic Alzheimer’s disease) that have only one or no copies of the apolipoprotein E ε4 (ApoE ε4) gene.